AstraZeneca takes back marketing of Symbicort Turbuhaler in Japan

17 January 2019

The sale and distribution of Symbicort (budesonide/formoterol)Turbuhaler30 doses and Symbicort Turbuhaler60 doses, the inhalation dry-powder treatment for asthma and chronic obstructive pulmonary disease (COPD), conducted by Astellas Pharma (TYO: 4503) in Japan will be transferred to the Japanese subsidiary of AstraZeneca (LSE: AZN), and the co-promotion by Astellas and AstraZeneca KK will be terminated on July 30, 2019.

AstraZeneca KK will solely distribute and promote the product in Japan from July 31, 2019. The termination of the sale and distribution by Astellas and the co-promotion by both companies of the product is due to the expiration of the sale and co-promotion agreement concluded in 2009 by Astellas and AstraZeneca.

Globally, Symbicort is AstraZeneca’s top-selling product, generating sales of $619 million in the third quarter of 2018, though down 7% on the like year-earlier period.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK